{"id":"NCT01155999","sponsor":"Laboratoires Thea","briefTitle":"Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2011-02","completion":"2011-02","firstPosted":"2010-07-02","resultsPosted":"2014-10-29","lastUpdate":"2014-10-29"},"enrollment":286,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Purulent Bacterial Conjunctivitis"],"interventions":[{"type":"DRUG","name":"T1225","otherNames":[]},{"type":"DRUG","name":"Tobramycin","otherNames":[]}],"arms":[{"label":"T1225","type":"EXPERIMENTAL"},{"label":"Tobramycin","type":"ACTIVE_COMPARATOR"}],"summary":"Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.","primaryOutcome":{"measure":"The Primary Efficacy Variable Was Clinical Cure in the Worse Eye on Day 3","timeFrame":"Day 3","effectByArm":[{"arm":"T1225","deltaMin":48,"sd":null},{"arm":"Tobramycin","deltaMin":29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Day","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":1,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":146},"commonTop":[]}}